[Form 4] Bio-Techne Corp. Insider Trading Activity

Rhea-AI Filing Summary

Roeland Nusse, a director of Bio-Techne Corporation (TECH), reported option exercises and share sales on 08/25/2025. He exercised 17,040 stock options with an exercise price of $21.84 and simultaneously sold 17,040 common shares at a weighted average price of $56.3608, reducing his reported beneficial ownership to 44,559 shares. Table II shows Nusse retains multiple outstanding option grants exercisable into common stock, including 17,040 options exercisable through 10/28/2025 and other option tranches with exercise prices from $25.30 to $128.81. The Form 4 was submitted via attorney-in-fact on 08/27/2025.

Positive

• Transparent disclosure of exercise, sale, weighted average sale price, and option vesting terms
• Director retains significant equity and option exposure after the transactions (44,559 shares plus multiple outstanding options)

Negative

• Reported beneficial ownership decreased following sale of 17,040 shares
• Insider sale of exercised shares could be perceived as unlocking personal liquidity

Insights

Financial Analyst

TL;DR: Routine insider option exercise with concurrent sale; principal effect is modest reduction in reported holdings.

The filing documents a common pattern where an insider exercises vested options at $21.84 and sells the same number of shares at a materially higher weighted average price ($56.3608). This realizes value for the reporting person while leaving significant remaining equity and option exposure. The reported beneficial ownership declined to 44,559 shares, but the director still holds multiple option tranches across years, preserving upside participation. The transaction appears procedural rather than signaling a material corporate event.

Corporate Governance Expert

TL;DR: Disclosure is complete and timely; transaction was reported by attorney-in-fact and includes explanatory footnotes.

The Form 4 includes required details: transaction codes, weighted average sale price footnote, option vesting mechanics, and an attorney-in-fact signature dated 08/27/2025. The filing clarifies that the sale price is a weighted average across multiple trades and discloses vesting terms for the most recent option grant. From a governance standpoint this meets SEC reporting expectations and provides transparency on insider liquidity and remaining equity incentives.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nusse Roeland

(Last) (First) (Middle)

614 MCKINLEY PL NE

(Street)

MINNEAPOLIS MN 55413

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/25/2025		M		17,040	A	$21.84	61,599	D
Common Stock	08/25/2025		S		17,040	D	$56.3608(1)	44,559	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$21.84	08/25/2025		M			17,040	10/29/2016	10/28/2025	Common Stock	17,040	$0	0	D
Stock Options (Right to Buy)	$25.3							10/26/2017	10/27/2026	Common Stock	15,940		15,940	D
Stock Options (Right to Buy)	$31.26							10/25/2018	10/26/2027	Common Stock	12,500		12,500	D
Stock Options (Right to Buy)	$44.96							10/24/2019	10/25/2028	Common Stock	7,592		7,592	D
Stock Options (Right to Buy)	$50.41							10/24/2020	10/24/2029	Common Stock	8,044		8,044	D
Stock Options (Right to Buy)	$63.92							10/28/2021	10/29/2030	Common Stock	6,028		6,028	D
Stock Options (Right to Buy)	$128.81							10/27/2022	10/28/2031	Common Stock	2,532		2,532	D
Stock Options (Right to Buy)	$73.94							10/26/2023	10/27/2032	Common Stock	3,460		3,460	D
Stock Options (Right to Buy)	$61.51							10/24/2024	10/26/2033	Common Stock	3,937		3,937	D
Stock Options (Right to Buy)	$68.37							(2)	10/24/2034	Common Stock	3,511		3,511	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.21 to $56.33 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. The option vests on the earlier of the one year anniversary of the grant date (10/24/2024) or the date of Bio-Techne's 2025 annual meeting of shareholders.

	Andrew Nick as Attorney-in-Fact for Roeland Nusse pursuant to Power of Attorney previously filed	08/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Roeland Nusse (TECH) report on 08/25/2025?

He exercised 17,040 options at an exercise price of $21.84 and sold 17,040 common shares at a weighted average price of $56.3608 on 08/25/2025.

How many shares does Roeland Nusse beneficially own after the reported transactions?

The Form 4 reports 44,559 shares beneficially owned following the transactions.

Are there outstanding options reported for Roeland Nusse and what are key terms?

Yes. Table II lists multiple option grants, including 17,040 options exercisable through 10/28/2025 at $21.84 and other tranches with exercise prices from $25.30 to $128.81 and varying expiration dates.

Was the sale price for the disposed shares a single price?

No. The sale price reported ($56.3608) is a weighted average for multiple transactions priced between $56.21 and $56.33, per the footnote.

Who signed and filed the Form 4?

The filing was made by Andrew Nick as Attorney-in-Fact for Roeland Nusse pursuant to a previously filed Power of Attorney, dated 08/27/2025.